A practical reference on freeze-dried powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-03. Anything still debated is marked as such rather than presented as settled.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
== References == Brendon, Piers (2010). The Decline and Fall of the British Empire, 1781–1997 (1st Vintage books ed.). New York City: Vintage Books. ISBN 9780307388414. Cilliers, Jakkie (1985). Counter-Insurgency in Rhodesia (PDF). Beckenham, United Kingdom: Croom Helm. ISBN 0-7099-3412-2. Cline, Lawrence E. (2005). "Pseudo Operations and Counterinsurgency: Lessons from Other Countries" (PDF). Strategic Studies Institute, US Army War College. Cross, G. (2017). Dirty War: Rhodesia and Chemical Biological Warfare, 1975–1980. Helion & Company. ISBN 978-1-911512-12-7. Dzimbanhete, Jephias Andrew (March 2017). "Reverberations of Rhodesian Propaganda in Narratives of Zimbabwe's Liberation War". Journal of Pan African Studies. 10 (1): 295–307. Evans, Michael (June 2007). "The Wretched of the Empire: Politics, Ideology and Counterinsurgency in Rhodesia, 1965–80". Small Wars & Insurgencies. 18 (2): 175–195. doi:10.1080/09574040701400601. S2CID 144153887. Gatchel, Theodore L. (2008). "Pseudo Operations – A Double Edged Sword of Counterinsurgency". In Norwitz, Jeffery H. (ed.). Armed Groups: Studies in National Security, Counterterrorism, and Counterinsurgency. Newport, Rhode Island: US Naval War College. pp. 61–74. ISBN 9781884733529. Martinez, Ian (December 2002). "The History of the Use of Bacteriological and Chemical Agents during Zimbabwe's Liberation War of 1965–80 by Rhodesian Forces". Third World Quarterly. 23 (6): 1159–1179. doi:10.1080/0143659022000036595. ISSN 0143-6597. JSTOR 3993569. S2CID 145729695. McLaughlin, Peter (August 1991).
Historically, brown meal was what remained after about 90% of the coarse, outer bran and 74% of pure endosperm or fine flour was removed from the whole grain. Using slightly different extraction numbers, brown meal, representing 20% of the whole grain, was itself composed of about 15% fine bran and 85% white flour. In 1848 it was asserted grain millers knew only of bran and endosperm, but by 1912 it was more widely known that brown meal included the germ.
== Prescription labels == Medication packaging includes a document that provides information about that drug and its use. In the US, this information is overseen by the Center for Drug Research and Evaluation (CDER), a branch of the Food and Drug Administration (FDA). For prescription medications, the insert is technical, and provides information for medical professionals about how to prescribe the drug. Package inserts for prescription drugs often include a separate document called a "patient package insert" with information written in plain language intended for the end-user -- the person who will take the drug or administer the drug to another person. Inserts for over-the-counter medications are also written plainly. In the US the document is called "prescribing information" or the "package insert" (PI) and layperson's document is called the "patient package insert" (PPI). In Europe the technical document is called the "summary of product characteristics" and the document for end-users is called the "package leaflet". The bottle or box also has information printed on it, intended for the person taking the medication.
Sources: en.wikipedia.org
A preservative is a substance or a chemical that is added to products such as food products, beverages, pharmaceutical drugs, paints, biological samples, cosmetics, wood, and many other products to prevent decomposition by microbial growth or by undesirable chemical changes. In general, preservation is implemented in two modes, chemical and physical. Chemical preservation entails adding chemical compounds to the product. Physical preservation entails processes such as refrigeration or drying. Preservative food additives reduce the risk of foodborne infections, decrease microbial spoilage, and preserve fresh attributes and nutritional quality. Some physical techniques for food preservation include dehydration, UV-C radiation, freeze-drying, and refrigeration. Chemical preservation and physical preservation techniques are sometimes combined.
=== Industrial, scientific, medical === The ISM bands were initially reserved for non-communications uses of RF energy, such as microwave ovens, radio-frequency heating, and similar purposes. However, in recent years the largest use of these bands has been by short-range low-power communications systems, since users do not have to hold a radio operator's license. Cordless telephones, wireless computer networks, Bluetooth devices, and garage door openers all use the ISM bands. ISM devices do not have regulatory protection against interference from other users of the band.
protomer Any molecular subunit from which a larger polymeric macromolecule is built, including those subunits which are not strictly monomers and can themselves be divided into subunits. For example, a heterodimer of tubulin proteins is the protomer for microtubule assembly.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.